ADMA BIOLOGICS, INC. (ADMA) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ADMA BIOLOGICS, INC. Do?
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. ADMA BIOLOGICS, INC. (ADMA) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Adam S. Grossman and employs approximately 530 people, headquartered in RAMSEY, New Jersey. With a market capitalization of $2.2B, ADMA is one of the notable companies in the Healthcare sector.
ADMA BIOLOGICS, INC. (ADMA) Stock Rating — Reduce (April 2026)
As of April 2026, ADMA BIOLOGICS, INC. receives a Reduce rating with a composite score of 42.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ADMA ranks #2,796 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ADMA BIOLOGICS, INC. ranks #387 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ADMA Stock Price and 52-Week Range
ADMA BIOLOGICS, INC. (ADMA) currently trades at $9.71. The stock lost $0.23 (2.3%) in the most recent trading session. The 52-week high for ADMA is $25.67, which means the stock is currently trading -62.2% from its annual peak. The 52-week low is $13.76, putting the stock -29.4% above its annual trough. Recent trading volume was 3.9M shares, reflecting moderate market activity.
Is ADMA Overvalued or Undervalued? — Valuation Analysis
ADMA BIOLOGICS, INC. (ADMA) carries a value factor score of 69/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 16.52x, compared to the Healthcare sector average of 23.63x — a discount of 30%. The price-to-book ratio stands at 4.62x, versus the sector average of 2.75x. The price-to-sales ratio is 4.49x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ADMA trades at 12.92x EV/EBITDA, versus 6.34x for the sector.
Overall, ADMA's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
ADMA BIOLOGICS, INC. Profitability — ROE, Margins, and Quality Score
ADMA BIOLOGICS, INC. (ADMA) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 28.0%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 21.4% versus the sector average of -33.1%.
On a margin basis, ADMA BIOLOGICS, INC. reports gross margins of 53.6%, compared to 71.5% for the sector. The operating margin is 34.1% (sector: -66.1%). Net profit margin stands at 27.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 25.2% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
ADMA Debt, Balance Sheet, and Financial Health
ADMA BIOLOGICS, INC. has a debt-to-equity ratio of 15.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.71x, indicating strong short-term liquidity. Total debt on the balance sheet is $72M. Cash and equivalents stand at $61M.
ADMA has a beta of 1.11, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ADMA BIOLOGICS, INC. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
ADMA BIOLOGICS, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, ADMA BIOLOGICS, INC. reported revenue of $491M and earnings per share (EPS) of $0.62. Net income for the quarter was $133M. Gross margin was 53.6%. Operating income came in at $168M.
In FY 2025, ADMA BIOLOGICS, INC. reported revenue of $510M and earnings per share (EPS) of $0.62. Net income for the quarter was $147M. Gross margin was 57.4%. Revenue grew 19.6% year-over-year compared to FY 2024. Operating income came in at $191M.
In Q3 2025, ADMA BIOLOGICS, INC. reported revenue of $134M and earnings per share (EPS) of $0.15. Net income for the quarter was $36M. Gross margin was 56.3%. Revenue grew 12.0% year-over-year compared to Q3 2024. Operating income came in at $51M.
In Q2 2025, ADMA BIOLOGICS, INC. reported revenue of $122M and earnings per share (EPS) of $0.14. Net income for the quarter was $34M. Gross margin was 55.1%. Revenue grew 13.8% year-over-year compared to Q2 2024. Operating income came in at $43M.
Over the past 8 quarters, ADMA BIOLOGICS, INC. has demonstrated a growth trajectory, with revenue expanding from $107M to $491M. Investors analyzing ADMA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ADMA Dividend Yield and Income Analysis
ADMA BIOLOGICS, INC. (ADMA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ADMA Momentum and Technical Analysis Profile
ADMA BIOLOGICS, INC. (ADMA) has a momentum factor score of 20/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.
ADMA vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ADMA BIOLOGICS, INC. (ADMA) ranks #387 out of 838 stocks based on the Blank Capital composite score. This places ADMA in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ADMA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ADMA vs S&P 500 (SPY) comparison to assess how ADMA BIOLOGICS, INC. stacks up against the broader market across all factor dimensions.
ADMA Next Earnings Date
No upcoming earnings date has been announced for ADMA BIOLOGICS, INC. (ADMA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ADMA? — Investment Thesis Summary
The quantitative profile for ADMA BIOLOGICS, INC. suggests caution. The value score of 69/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 20/100, a headwind for near-term performance. High volatility (stability score 36/100) increases portfolio risk.
In summary, ADMA BIOLOGICS, INC. (ADMA) earns a Reduce rating with a composite score of 42.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ADMA stock.
Related Resources for ADMA Investors
Explore more research and tools: ADMA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ADMA head-to-head with peers: ADMA vs AZN, ADMA vs SLGL, ADMA vs VMD.